Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009

Southern Medical Journal

Volumn 104, Issue 2, 2011, Pages 95-101

  Youmans, Eren ^a   Tripathi, Avnish ^a   Albrecht, Helmut ^a   Gibson, James J ^a   Duffus, Wayne A ^a  

^a NONE

Author keywords

antiretroviral therapy; HIV drug resistance; protease inhibitors; reverse transcriptase inhibitors; surveillance

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; DEMOGRAPHY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; TRANSMITTED DRUG RESISTANCE; TREATMENT OUTCOME; UNITED STATES; VIROTHERAPY; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; SOUTH CAROLINA; YOUNG ADULT;

EID: 79251627369     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181fcd75b     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Novak RM, Chen L, MacArthur RD, et al; Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40:468-474.
3. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999;13: F35-F43.
4. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.
5. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006;41:439-446.
6. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007;8:1-8.
7. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
8. Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis 2009;13:552-559.
9. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003;5:140-155.
10. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis 2000;182:330-333.
11. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004;189:2174-2180.
12. Wensing AM, van de Vijver DA, Angarano G, et al; SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-966.
13. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999;13: F17-F21.
14. Yerly S, von Wyl V, Ledergerber B, et al; Swiss HIV Cohort Study. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007;21:2223-2229.
15. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17:138-145.
16. Wheeler WH, Ziebell RA, Zabina H, et al; Variant, Atypical, and Resistant HIV Surveillance Group. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U. S.-2006. AIDS 2010;24:1203-1212.
17. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
18. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16:1511-1519.
19. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
20. Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009;14:673-678.
21. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001;26 Suppl 1: S25-S33.
22. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1666.
23. Easterbrook PJ, Newson R, Ives N, et al. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr 2001;27:350-364.
24. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and crossresistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445-448.
25. Murphy EL, Collier AC, Kalish LA, et al; Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
26. Hammer SM, Saag MS, Schechter M, et al; International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
27. Craw JA, Gardner LI, Marks G, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr 2008;47:597-606.
28. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
29. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001;14:23-28.
30. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002;76:1753-1761.
31. CDC's Clinical Studies of Pre-Exposure Prophylaxis for HIV Prevention [CDC web site]. 2010. Available at: http://www.cdc.gov/hiv/prep/resources/qa/ index.htm. Accessed January 4, 2010.
32. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004;37:1570-1573.
33. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18:1683-1689.